U.S. Markets closed

Microbix Biosystems Inc. (MBX.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
0.38+0.01 (+2.70%)
At close: 11:06AM EDT

Microbix Biosystems Inc.

265 Watline Avenue
Mississauga, ON L4Z 1P3
Canada
905-361-8910
http://www.microbix.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees70

Key Executives

NameTitlePayExercisedAge
Mr. William J. GastleFounder & Exec. Chairman197.75kN/AN/A
Mr. Cameron GroomePres, CEO & DirectorN/AN/AN/A
Mr. Philip CasselliSr. VP of Sales, Bus. Devel. and Marketing179.54kN/AN/A
Mr. Vaughn C. Embro-PantalonyExec. Director221.5kN/AN/A
Mr. Kevin J. CassidyVP of Biopharmaceuticals150kN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Microbix Biosystems Inc. develops, manufactures, and sells biological products and technologies in North America, Europe, and internationally. The company manufactures and sells cell culture-based biological products, as well as infectious disease antigens. It offers infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for molecular diagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. In addition, the company manufactures inactivated viral antigen detection proficiency testing samples; and unassayed control reagents for in vitro molecular diagnostic assays. Its pipeline of technologies and products include LumiSort semen sexing technology for the livestock industries; Kinlytic, a thrombolytic drug for the treatment of life-threatening pulmonary embolism and clot obstructed intravenous catheters; and VIRUSMAX, a technology used to enhance influenza vaccine manufacturing yields. The company offers products for human health applications in the diagnostic and animal reproduction markets. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.

Corporate Governance

Microbix Biosystems Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.